Библиография

1. 1. Provensi G., Blandina P., and Passani M. B. The histaminergic system as a target for the prevention of obesity and metabolic syndrome. Neuropharmacology, 106, 3–12 (2016). DOI: 10.1016/j.neuropharm.2015.07.002
2. 2. Lian J., Huang X. F., Pai N., and Deng C. Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications. Pharmacol Res., 106, 51– 63 (2016). DOI: 10.1016/j.phrs.2016.02.011
3. 3. Takeda N., Matsuda K., Fukuda J., Sato G., Uno A., and Kitahara T. Vestibular compensation: Neural mechanisms and clinical implications for the treatment of vertigo. Auris Nasus Larynx, 51 (2), 328–336 (2024).DOI: 10.1016/j.anl.2023.11.009
4. 4. Lacour M. Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. J. Vestib Res., 23 (3), 139–151 (2013). DOI: 10.3233/VES-130496
5. 5. Wu P., Cao W., Hu Y., and Li H. Effects of vestibular rehabilitation, with or without betahistine, on managing residual dizziness after successful repositioning manoeuvres in patients with benign paroxysmal positional vertigo: a protocol for a randomised controlled trial. BMJ Open, 9 (6), e026711 (2019).DOI: 10.1136/bmjopen-2018-026711
6. 6. Mani V . and Arfeen M. Betahistine's neuroprotective actions against lipopolysaccharide-induced neurotoxicity: Insights from experimental and computational studies. Brain Sci., 14 (9), 876 (2024).DOI: 10.3390/brainsci14090876
7. 7. Mani V. Betahistine protects doxorubicin-induced memory deficits via cholinergic and anti-inflammatory pathways in mouse brain. Int. J. Pharmacol., 17 (8), 584–595 (2021).
8. 8. Angelaki D. E., Klier E. M., and Snyder L. H. A vestibular sensation: probabilistic approaches to spatial perception. Neuron, 64 (4), 448–461(2009).DOI: 10.1016/j.neuron.2009.11.010
9. 9. Strupp M., Dlugaiczyk J., Ertl-Wagner B. B., Rujescu D., Westhofen M., and Dieterich M. Vestibular disorders. Dtsch. Arztebl. Int., 117 (17), 300–310 (2020).DOI: 10.3238/arztebl.2020.0300
10. 10. Pokhrel P. K., Hall R., Pendergrass M., and Kaur J. Vestibular disorders. Prim. Care: Clinics in Office Practice, 52 (1), 15–25 (2025). DOI: 10.1016/j.pop.2024.09.004
11. 11. Giacomello M., Pyakurel A., Glytsou C., and Scorrano L. The cell biology of mitochondrial membrane dynamics. Nat. Rev. Mol. Cell Biol., 21, 204–224 (2020).DOI: 10.1038/s41580-020-0210-12
12. 12. Song J., Herrmann J.M., and Becker T. Quality control of the mitochondrial proteome. Nat. Rev. Mol. Cell Biol., 22, 54–70 (2021). DOI: 10.1038/s41580-020-00300-2
13. 13. Kondadi A. K. and Reichert A. S. Mitochondrial dynamics at different levels: From cristae dynamics to interorganellar cross talk. Annu. Rev. Biophys., 53 (1), 147–168 (2024). DOI: 10.1146/annurev-biophys-030822-020736
14. 14. Imaizumi M., Miyazaki S., and Onodera K. Effects of betahistine, a histamine H1 agonist and H3 antagonist, in a light/dark test in mice. Methods Find. Exp. Clin. Pharmacol., 18 (1), 19–24 (1996). PMID: 8721252
15. 15. The ALLEN Mouse Brain Atlas: https://mouse.brainmap.org/static/atlas
16. 16. Mikheeva I. B., Malkov A. E., Pavlik L. L., Arkhipov V. I., and Levin S. G. Effect of TGF-beta1 on long-term synaptic plasticity and distribution of AMPA receptors in the CA1 field of the hippocampus. Neurosci. Lett., 704, 95–99 (2019). DOI: 10.1016/j.neulet.2019.04.005
17. 17. Zhang Z. H., Liu L. P., Fang Y., Wang X. C., Wang W., Chan Y. S., Wang L., Li H., Li Y. Q., and Zhang F. X. A new vestibular stimulation mode for motion sickness with emphatic analysis of pica. Front. Behav. Neurosci., 16, 882695 (2022). DOI: 10.3389/fnbeh.2022.882695
18. 18. Curthoys I. S. and Halmagyi G. M. Vestibular compensation: A review of the oculomotor, neural, and clinical consequences of unilateral vestibular loss. J. Vestibular Res., 5 (2), 67–107 (1995).
19. 19. Dutia M. B. Mechanisms of vestibular compensation: Recent advances. Curr. Opin. Otolaryngology & Head and Neck Surg., 18 (5), 420–424(2010).
20. 20. Smith P. F. and Darlington C. L. Neuroplasticity and vestibular compensation. J. Vestibular Res., 23 (1), 3–15 (2013).
21. 21. Han B., Jiang W., Cui P., Zheng K., Dang C., Wang J., Li H., Chen L., Zhang R., Wang Q. M., Ju Z., and Hao J. Microglial PGC-1α protects against ischemic brain injury by suppressing neuroinflammation. Genome Med., 13 (1), 47 (2021). DOI: 10.1186/s13073-021-00863-5
22. 22. Liu X., Li T., Tu X., Xu M., and Wang J. Mitochondrial fission and fusion in neurodegenerative diseases: Ca2+ signalling. Mol. Cell Neurosci., 132, 103992 (2025).DOI: 10.1016/j.mcn.2025.103992
23. 23. Schrepfer E. and Scorrano L. Mitofusins, from Mitochondria to Metabolism. Mol. Cells, 61 (5), 683–694 (2016). DOI: 10.1016/j.molcel.2016.02.022
24. 24. Bell M. B., Bush Z., McGinnis G. R., and Rowe G. C. Adult skeletal muscle deletion of Mitofusin 1 and 2 impedes exercise performance and training capacity. J. Appl. Physiol., 126 (2), 341–353(2019).DOI: 10.1152/japplphysiol.00719.2018
25. 25. Shields L. Y., Kim H., Zhu L., Haddad D., Berthet A., Pathak D., Lam M., Ponnusamy R., Diaz-Ramirez L. G., Gill T. M., Sesaki H., Mucke L., and Nakamura K. Dynamin-related protein 1 is required for normal mitochondrial bioenergetic and synaptic function in CA1 hippocampal neurons. Cell Death Dis., 6 (4), e1725 (2015). DOI: 10.1038/cddis.2015.94
26. 26. Cho B., Choi S. Y., Cho H. M., Kim H. J., and Sun W. Physiological and pathological significance of dynaminrelated protein 1 (drp1)-dependent mitochondrial fission in the nervous system. Exp. Neurobiol., 22 (3), 149–157 (2013). DOI: 10.5607/en.2013.22.3.149
27. 27. Galluzzi L., Baehrecke E. H., Ballabio A., Boya P., Bravo-San Pedro J. M., Cecconi F., Choi A. M., Chu C. T., Codogno P., Colombo M. I., Cuervo A. M., Debnath J., Deretic V., Dikic I., Eskelinen E. L., Fimia G. M., Fulda S., Gewirtz D. A., Green D. R., Hansen M., Harper J. W., Jäättelä M., Johansen T., Juhasz G., Kimmelman A. C., Kraft C., Ktistakis N. T., Kumar S., Levine B., Lopez-Otin C., Madeo F., Martens S., Martinez J., Melendez A., Mizushima N., Münz C., Murphy L. O., Penninger J. M., Piacentini M., Reggiori F., Rubinsztein D. C., Ryan K. M., Santambrogio L., Scorrano L., Simon A. K., Simon H. U., Simonsen A., Tavernarakis N., Tooze S. A., Yoshimori T., Yuan J., Yue Z., Zhong Q., and Kroemer G. Molecular definitions of autophagy and related processes. EMBO J., 36 (13), 1811–1836 (2017).DOI: 10.15252/embj.201796697
28. 28. Mouli P. K., Twig G., and Shirihai O. S. Frequency and selectivity of mitochondrial fusion are key to its quality maintenance function. Biophys J., 96 (9), 3509–3518 (2009). DOI: 10.1016/j.bpj.2008.12.3959
29. 29. Nah J., Yuan J., and Jung Y. K. Autophagy in neurodegenerative diseases: from mechanism to therapeutic approach. Mol. Cells, 38 (5), 381–389 (2015).DOI: 10.14348/molcells.2015.0034
30. 30. Zhu J., Wang K. Z., and Chu C. T. After the banquet: mitochondrial biogenesis, mitophagy, and cell survival. Autophagy, 9 (11), 1663–1676 (2013). DOI: 10.4161/auto.241
31. 31. Guth P. S., Shipon S., Valli P., Mira E., and Benvenuti C. A pharmacological analysis of the effects of histamine and betahistine on the semicircular canal. In: Vertigine e Betaistine, Ed. by C. Benvenuti (Formenti, Milan, Italy, 2000), pp. 19–30.
32. 32. Soto E., Chávez H., Valli P., Benvenuti C., and Vega R. Betahistine produces a postsynaptic inhibition on the excitability of the primary afferent neurons in the vestibular endorgans. Acta Otolaryngol., 545 (Suppl.), 19–24 (2001). DOI: 10.1080/000164801750388045
33. 33. Chávez O., Vega R., and Soto E. Histamine (H3) receptors modulate the excitatory amino acid receptor response of the vestibular afferent. Brain Res., 1064, 1–9 (2005). DOI: 10.1016/j.brainres.2005.10.027